{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-24-008706","form_type":"8-K","ticker":"ALZN","cik":"0001677077","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.538957+00:00","generated_at":"2026-06-02T06:21:28.692133+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Alzamend Neuro enters $25M financing via preferred stock and warrants at 15% dividend","bullets":["Initial $500,000 closing of 50 Series A Preferred shares at $10,000 each; up to $25M total.","Preferred shares convertible at floor $0.25 or 80% of 3-day lowest close (capped at $1.50).","Warrants for up to 20M common shares at $1.25, exercisable for 5 years, subject to adjustment.","15% annual cumulative dividend payable in cash or additional preferred shares at investor's election.","Proceeds to fund additional clinical trials for Alzheimer's, bipolar, MDD, PTSD; closing expected May 10, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-24-008706","json":"https://secwatch.observer/filing/0001214659-24-008706.json","markdown":"https://secwatch.observer/filing/0001214659-24-008706.md","text":"https://secwatch.observer/filing/0001214659-24-008706.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924008706/0001214659-24-008706-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924008706/p582408k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:21:28.692133+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2073b1ad1ad14a966063ca39ce54b21788d71897","claim":"Alzamend Neuro, Inc. entered into Securities Purchase Agreement with a sophisticated investor valued at up to $25,000,000.00 (effective 2024-05-08).","evidence_excerpt":"On May 8, 2024 (the “ Execution Date ”), Alzamend Neuro, Inc., a Delaware corporation (the “ Company ”) entered into a Securities Purchase Agreement (the “ Agreement ”) with a sophisticated investor (the “ Purchaser ”), pursuant to which the Company agreed to sell to the Purchaser up to 2,500 shares of Series A Convertible Preferred Stock (the “ Series A Preferred Stock ”) and warrants (the “ Warrants ”) to purchase shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) for a total purchase price of up to $25,000,000.00 (the “ Financing ”) in several tranche closings","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924008706/0001214659-24-008706-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"a sophisticated investor"},{"label":"Value","value":"up to $25,000,000.00"},{"label":"Effective","value":"2024-05-08"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}